Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
Conditions: Breast Atypical Hyperplasia; Breast Carcinoma; Breast Ductal Carcinoma In Situ; Breast Lobular Carcinoma In Situ Interventions: Procedure: Biospecimen Collection; Procedure: Mammography; Drug: Omega-3-Acid Ethyl Esters; Other: Questionnaire Administration; Procedure: Random Periareolar Fine-Needle Aspiration; Drug: Tamoxifen Sponsors: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
Conditions: Breast Carcinoma; Breast Ductal Carcinoma In Situ; Breast Lobular Carcinoma In Situ; Estrogen Receptor-Positive Breast Carcinoma Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Mammography; Other: Questionnaire Administration; Drug: Tamoxifen Sponsors: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 28, 2023 Category: Research Source Type: clinical trials
Pure Florid and Pleomorphic Lobular Carcinoma in Situ of the Breast: Towards an Increasingly Uniform Management
Conditions: Pleomorphic Lobular Breast Carcinoma in Situ; Breast Florid Lobular Carcinoma in Situ Interventions: Procedure: Surgical wide local excision; Procedure: Cavity shaving; Procedure: Excision margin surgical clearance; Radiation: Adjuvant Radiotherapy; Biological: Adjuvant Hormone Therapy Sponsors: Istituto Oncologico Veneto IRCCS Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2023 Category: Research Source Type: clinical trials
Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in Invasive Lobular Carcinoma
Condition: Carcinoma, Lobular Intervention: Drug: [18F]fluoroestradiol (FES) Sponsor: Asan Medical Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 25, 2023 Category: Research Source Type: clinical trials
Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ
Conditions: Atypical Hyperplasia; Lobular Carcinoma in Situ Interventions: Drug: Tamoxifen; Drug: Topical 4-OHT( 4-hydroxytamoxifen)gel 2 mg/each breast/day; Drug: Placebo Sponsor: Amy C. Degnim Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 30, 2020 Category: Research Source Type: clinical trials
